Toxicology & Pharmacology Conference to be held in Rome, Italy during March 23 - 24 2020.
Toxicology and Risk Assessment
Get link
Facebook
X
Pinterest
Email
Other Apps
The risk assessment is based on a chemical characterization of the test article, published information from the toxicological literature, and tolerable exposure limits, which may be adopted from published guidelines or derived on the basis of available toxicology data. The objective of a toxicological risk assessment is to evaluate the potential health risks associated with exposure to leachable impurities, contaminants, or other residues in a medical device or drug product. Based on the data from a chemical characterization, the risk assessment is to make a determination as to whether the release of chemicals during the use of a medical device or drug formulation may represent a toxicological risk that is unacceptable from a regulatory perspective. TRA is a research-based evaluation comprised of four activities: Hazard identification and data evaluation; Exposure assessment; Dose-response analysis; Risk characterization.
Drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, the process of drug development can continue, and, if successful, clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. A toxicology screen is a test that determines the approximate amount and type of legal or illegal drugs that taken. It may be used to screen for drug abuse , to monitor a substance abuse problem, or to evaluate drug intoxication or overdose. Toxicology screening can be done fairly quickly. The test is most often done using a urine or blood sample. In some cases, a sample of saliva or hair may be used. The results can show the presence of one specific drug or a variety of drugs at once. Further testing may be needed to determ...
Drug safety in the development process, new biomarkers are needed which can reduce the time-consuming process and cost of drug development. Traditional indicators of target organ toxicity used in preclinical drug safety studies consist of a battery of clinical pathology parameters in blood and urine coupled with histopathologic examination of altered tissues. Researching the translational safety biomarker is a process that investigates one characteristic of the biomarker, i.e. noninvasive, and translates between species. The safety biomarker should be validated and preclinically and clinically qualified. Several kidney biomarkers in the context of preclinical development and clinical trials are presented in this chapter. Application of safety biomarkers in different phases of drug development, in particular for kidney, liver, heart, vascular vessels, lung, central nervous system, and lipid/carbohydrate metabolism, is described. For more: http://www.globalepisteme.org/Conferenc...
Nanotoxicology is the study of the toxicity of nanomaterials. Because of quantum size effects and large surface area to volume ratio, nanomaterials have unique properties compared with their larger counterparts. Nanotoxicology is a branch of bionanoscience which deals with the study and application of toxicity of nanomaterials. Nanomaterials , even when made of inert elements like gold, become highly active at nanometer dimensions. Nanotoxicological studies are intended to determine whether and to what extent these properties may pose a threat to the environment and to human beings. For instance, Diesel nanoparticles have been found to damage the cardiovascular system in a mouse model. For more: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/ For abstract submission: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/submitabstract Contact us: toxicology@globalepisteme.com
Comments
Post a Comment